ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1982

Five Years of Treatment to Target in Early Active Rheumatoid Arthritis: Prevalence and Predictors of Vertebral Fractures

L. Dirven1, M. van den Broek2, A.J. Peeters3, N. Riyazi4, P.J.S.M. Kerstens5, T.W.J. Huizinga1, C.F. Allaart1 and W. F. Lems6, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, 4Rheumatology, Haga Hospital, The Hague, Netherlands, 5Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 6Rheumatology, VU University medical center, Amsterdam, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Osteoporosis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoporosis and Metabolic Bone Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:
Vertebral fractures (VFs) are more common in patients with rheumatoid arthritis (RA) compared to the general population. It is suggested that an appropriate control of disease, generally more effectively achieved with disease activity score (DAS)-steered treatment strategies, may prevent the development of vertebral fractures. The prevalence of vertebral fractures after 5 years of DAS-steered treatment in patients with early active RA was determined and the association of VFs with disease activity, functional ability and bone mineral density (BMD) over time was investigated.
Methods:
Five-year radiographs of the lateral thoracic and lumbar spine of 275 patients in the BeSt study, a randomized trial comparing four treatment strategies, were available. Treatment adjustments were made every 3 months aiming at a DAS≤2.4. Vertebral fractures were assessed using the Genant method, with a fracture defined as loss of height reduction >20% in one vertebra. BMDs of the spine and hip were measured with dual energy X-ray absorptiometry. With linear mixed models, DAS and Health Assessment Questionnaire (HAQ) scores over 5 years were compared for patients with and without VFs. With GEE the association between BMD and VFs was determined.
Results:
At baseline patients were on average 54 years old and most were female (67%), of whom 18% were postmenopausal. Mean DAS was 4.4 and mean HAQ score was 1.3. After 5 years of DAS steered treatment, VFs were observed in 41/275 patients (15%). No difference in prevalence was found when stratified for gender, treatment with prednisone and menopausal status. Disease activity over time was higher in patients with VFs, with a mean difference of 0.20 (95% CI:0.05-0.36). HAQ scores were higher in patients with VFs, independent of disease activity, with a mean difference of 0.12 (95% CI:0.02-0.2). Although values were slightly lower over time in patients with vertebral fractures, mean BMDs in the spine and hip over time were not independently associated with VFs (OR 0.99, 95%CI:0.78-1.25 and 0.94, 95%CI: 0.65-1.36, respectively). Higher age was independently associated with VFs (OR 1.06, 95%CI:1.02-1.09).
Conclusion:
After 5 years of DAS-steered treatment, 15% of these RA patients had vertebral fractures (VFs). Higher age was associated with the presence of VFs, but mean BMDs in the hip and spine were not. VFs are associated with more disability, independent of disease activity. Patients with VFs have a slightly higher disease activity over time, suggesting that optimal disease activity suppression may prevent VFs.


Disclosure:

L. Dirven,
None;

M. van den Broek,
None;

A. J. Peeters,
None;

N. Riyazi,
None;

P. J. S. M. Kerstens,
None;

T. W. J. Huizinga,
None;

C. F. Allaart,
None;

W. F. Lems,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/five-years-of-treatment-to-target-in-early-active-rheumatoid-arthritis-prevalence-and-predictors-of-vertebral-fractures/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology